Impact of dose-escalation schemes and drug discontinuation on weight loss outcomes with liraglutide 3.0 mg: A model-based approach.
Saved in:
| Title: | Impact of dose-escalation schemes and drug discontinuation on weight loss outcomes with liraglutide 3.0 mg: A model-based approach. |
|---|---|
| Authors: | Papathanasiou T; Novo Nordisk A/S, Quantitative Clinical Pharmacology, Søborg, Denmark.; Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark., Strathe A; Novo Nordisk A/S, Quantitative Clinical Pharmacology, Søborg, Denmark., Agersø H; Novo Nordisk A/S, Quantitative Clinical Pharmacology, Søborg, Denmark., Lund TM; Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark., Overgaard RV; Novo Nordisk A/S, Quantitative Clinical Pharmacology, Søborg, Denmark. |
| Source: | Diabetes, obesity & metabolism [Diabetes Obes Metab] 2020 Jun; Vol. 22 (6), pp. 969-977. Date of Electronic Publication: 2020 Feb 19. |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 100883645 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1463-1326 (Electronic) Linking ISSN: 14628902 NLM ISO Abbreviation: Diabetes Obes Metab Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
